- Home
- » Tags
- » Milatuzumab
Top View
- Open Full Page
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- Orphan Drug Designations and Approvals List As of 06‐02‐2014 Governs July 1, 2014 ‐ September 30, 2014
- (12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
- (INN) for Biological and Biotechnological Substances
- 1 Enhanced Delivery of SN-38 to Human Tumor Xenografts with An
- Antibody Drug Conjugates Still Making Slow Progress
- Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
- First Experience with Daratumumab for Treatment of Relapsed-Refractory Multiple Myeloma
- Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
- Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
- Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
- Orphan Drug Designation List
- Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Antibody Drug Conjugates (ADC)
- Therapeutic Outcome of Early-Phase Clinical Trials in Multiple Myeloma: a Meta-Analysis Niels Van Nieuwenhuijzen1,2,Rowanfrunt 1, Anne M
- Sacituzumab Govitecan (IMMU-132)
- First-In-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab
- Prevention of Acute Graft-Versus-Host Disease in a Xenogeneic SCID
- Corporate Presentation June 2018
- Immune-Based Therapies in the Management of Multiple Myeloma Saurabh Zanwar 1,2,Bharatnandakumar1 and Shaji Kumar 1,2
- Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
- Milatuzumab-Conjugated Liposomes As Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74 B-Cell Malignancies
- Biotechnology Presented by America’S Biopharmaceutical Research Companies
- CD74 Deficiency Mitigates Systemic Lupus Erythematosus–Like
- Clinical Efficacy and Management of Monoclonal Antibodies Targeting CD38 and SLAMF7 in Multiple Myeloma
- Milatuzumab - Drugbank
- (12) Patent Application Publication (10) Pub. No.: US 2014/0363454 A1 Jackson Et Al
- Oncology Drugs in the Pipeline
- Cancer Cell Targeting: Why Are So Few Antibody-Drug Conjugates Fda Approved?
- Why Immunotherapy Fails in Multiple Myeloma
- Antibody-Drug Conjugates: the New Frontier of Chemotherapy
- Activated B-Cell
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- Milatuzumab–SN-38 Conjugates for the Treatment of Cd74þ Cancers
- Novel Targeted Therapies for Mantle Cell Lymphoma
- Understanding Immunotherapy and Lymphoma
- Oncology Drugs in the Pipeline
- The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post- Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance
- Immunotherapy in Multiple Myeloma
- Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- COMP Agenda of the 11-13 July 2016 Meeting
- Strategies and Challenges for the Next Generation of Antibody-Drug
- Immunomedics,® Inc
- (12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
- Antibody–Drug Conjugates: a Comprehensive Review Puregmaa Khongorzul1, Cai Jia Ling1, Farhan Ullah Khan2, Awais Ullah Ihsan3, and Juan Zhang1
- Current Antibody-Based Therapies for the Treatment of Multiple Myeloma